Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case-March 2024-www.financetom.com

Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case

Oct 7, 2025 8:08 AM

Oct 7 (Reuters) - A Los Angeles jury late on Monday

ordered Johnson & Johnson ( JNJ ) to pay $966 million to the family of a

woman who died from mesothelioma, finding the company liable in

the latest lawsuit alleging its baby powder products cause

cancer.

(Reporting by Diana Novak Jones; Editing by Chizu Nomiyama )

Previous page： Nukkleus Stock Soars To Fresh Highs On Tiltan Defense Tech Deal Next page： Update: Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Nukkleus Stock Soars To Fresh Highs On Tiltan Defense Tech Deal

Sep 2, 2025

Nukkleus Inc. ( NUKK ) shares soared on Tuesday after the company said it will acquire Israel-based Tiltan Software Engineering Ltd. in a $14 million deal. The acquisition, to be paid in a mix of cash and stock, is expected to close following regulatory approval and audited financials. The announcement underscores growing demand for AI-powered simulation and GPS-denied navigation tools...

Update: Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced

Sep 2, 2025

11:25 AM EDT, 09/02/2025 (MT Newswires) -- (Updates to include Arrowhead's stock movement in the headline and the first paragraph.) Arrowhead Pharmaceuticals ( ARWR ) shares rose 9.2% in recent Tuesday trading after the company announced a global licensing and collaboration agreement for its ARO-SNCA preclinical stage siRNA therapy to treat synucleinopathies, including Parkinson's disease, with Novartis ( NVS )...

Blue Bird Insider Sold Shares Worth $767,260, According to a Recent SEC Filing

Sep 2, 2025

11:25 AM EDT, 09/02/2025 (MT Newswires) -- Phil Horlock, Director, on August 28, 2025, sold 13,000 shares in Blue Bird ( BLBD ) for $767,260. Following the Form 4 filing with the SEC, Horlock has control over a total of 240,766 common shares of the company, with 240,766 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1589526/000157947725000018/xslF345X05/wk-form4_1756826178.xml Price: 57.75, Change: -0.64, Percent Change:...

Update: Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia

Sep 2, 2025

11:26 AM EDT, 09/02/2025 (MT Newswires) -- (Updates with recent stock movement in the headline and first paragraph.) Ionis Pharmaceuticals ( IONS ) shares were up more than 33% in recent Tuesday trading after the company reported topline data from phase 3 studies of olezarsen, which showed that the drug candidate significantly reduced fasting triglycerides and acute pancreatitis events in...